Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  elotuzumab
Find trials that include:  Any drugs shown
Results 1-9 of 9 for your search:
Start Over
Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-602, NCI-2016-00875, 2015-005699-21, NCT02726581
Bortezomib, Dexamethasone, and Lenalidomide with or without Elotuzumab in Treating Patients with Newly Diagnosed High-Risk Multiple Myeloma
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S1211, NCI-2012-01998, CDR0000738512, PS1211_A12PAMDREVW01, SWOG-S1211, NCT01668719
Elotuzumab, Lenalidomide, and Dexamethasone in Treating Patients with High-Risk Smoldering Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-338, NCI-2014-02644, NCT02279394
Elotuzumab and Lenalidomide after Stem Cell Transplant in Treating Patients with Newly Diagnosed Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0729, NCI-2015-00762, NCT02420860
Elotuzumab, Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-475, NCI-2016-00943, NCT02718833
Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CA204-125, NCI-2016-01039, 2014-003282-19, NCT02654132
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: CA204-185, NCI-2016-01231, 2016-000037-51, NCT02719613
Expanded Access Treatment Protocol CA204-143
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: CA204-143, NCI-2015-01188, NCT02368301
Start Over